A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV MEDI (delta)M2-2 Lot RSV(hash)002A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, RSV-Seropositive Children 12 to 59 Months of Age, and RSV-Seronegative Infants and Children 6 to 24 Months of Age.

Trial Profile

A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV MEDI (delta)M2-2 Lot RSV(hash)002A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, RSV-Seropositive Children 12 to 59 Months of Age, and RSV-Seronegative Infants and Children 6 to 24 Months of Age.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2015

At a glance

  • Drugs RSV MEDI deltaM2-2 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Dec 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 22 Jan 2014 Planned End Date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov
    • 23 Oct 2012 Planned End Date (1 May 2014) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top